Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11279906 | 0.84 | KCNN4 (0.52) | KCNN4KIF11MAPK1ALDH1A1TSHR | |
| SCHEMBL27675660 | 0.79 | KCNN4 (0.40) | KCNN4KIF11MAPK1ALDH1A1TSHR | |
| Biphenyl SCHEMBL7519251 | 0.76 | KCNN4 (0.44) | KCNN4KIF11MAPK1ALDH1A1TSHR | |
| SCHEMBL23112981 | 0.74 | KCNN4 (0.43) | KCNN4KIF11MAPK1ALDH1A1TSHR | |
| SCHEMBL18035826 | 0.74 | ALDH1A1 (0.44) | KCNN4KIF11MAPK1ALDH1A1 | |
| SCHEMBL7535593 | 0.74 | KCNN4 (0.39) | KCNN4KIF11MAPK1ALDH1A1TSHR | |
| SCHEMBL27860651 | 0.71 | KCNN4 (0.44) | KCNN4MAPK1ALDH1A1TSHRTAAR1 | |
| SCHEMBL654702 | 0.71 | MAPK13 (0.42) | KCNN4ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL2164357 | 0.70 | ESR1 (0.54) | KCNN4MAPK1ALDH1A1TSHRHDAC3 | |
| SCHEMBL294517 | 0.70 | ESR1 (0.54) | KCNN4MAPK1ALDH1A1TSHRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| US-20240228433-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2024-07-11 | — | — | US | disclosed |
| CN-118317970-A | Synthesis of 2' acetyl-ester protected nucleosides | 兆维生物科技公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024137756-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024118503-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11993626-B2 | Functionalized N-acetylgalactosamine analogs | HONGENE BIOTECH CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4355336-A1 | PRODRUGS OF DEOXYNUCLEOSIDES FOR TREATMENT OF MITOCHONDRIAL DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS | Zogenix, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11897914-B2 | Synthesis of 2′ protected nucleosides | HONGENE BIOTECH CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| CN-117500510-A | Deoxynucleoside prodrugs for treating mitochondrial diseases caused by unbalanced nucleotide pools | 周格尼克斯公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230416295-A1 | SYNTHESIS OF 2' PROTECTED NUCLEOSIDES | HONGENE BIOTECH CORPORATION | 2023-12-28 | — | — | US | disclosed |
| US-20130109850-A1 | MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012040523-A2 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011139702-A2 | MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139695-A2 | MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139911-A2 | LIPID FORMULATED SINGLE STRANDED RNA | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139699-A2 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| CN-1218001-C | Yellow toner compound and aqueous ink for ink-jet recording apparatus using the same | MITSUI CHEMICALS INC (JP) | 2005-09-07 | — | — | CN | disclosed |
| CN-1322227-A | Yellow toner compound and aqueous ink for ink-jet recording apparatus using the same | MITSUI CHEMICALS INC (JP) | 2001-11-14 | — | — | CN | disclosed |
| CN-1227555-A | Cytokine production inhibitors triazepine compounds, and intermediates thereof | JAPAN TOBACCO INC (JP) | 1999-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228433-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLRMT, POLR2E | KCNN4 4844/4885KIF11 1171/4885MAPK1 3564/4885 |
| US-11993626-B2 | Functionalized N-acetylgalactosamine analogs | FUT6, CSGALNACT1, GALNT6 | KCNN4 4331/4885KIF11 2735/4885MAPK1 4233/4885 |
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | KCNN4 4827/4885KIF11 1696/4885MAPK1 4718/4885 |
| US-20230416295-A1 | SYNTHESIS OF 2' PROTECTED NUCLEOSIDES | NSUN2, RNMT, RNGTT | KCNN4 4022/4885KIF11 3777/4885MAPK1 2950/4885 |
| US-20130109850-A1 | MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, POLRMT, RNGTT | KCNN4 4757/4885KIF11 1649/4885MAPK1 4552/4885 |
| US-11897914-B2 | Synthesis of 2′ protected nucleosides | NSUN2, RNMT, RNGTT | KCNN4 4007/4885KIF11 3733/4885MAPK1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.